Skip to main content
SpringerLink
Log in

Retinal Vascular Disease

  • Chapter
  • First Online:
Lee's Ophthalmic Histopathology

  • 1659 Accesses

Abstract

Ischaemic retinal vascular diseases ultimately lead to glaucoma and are found in the globes that are enucleated to relieve intractable pain in a blind eye. The clinical diagnosis is usually “neovascular glaucoma” with the addition of “central retinal vein occlusion” or “diabetes,” but occasionally, rarer entities such as retinopathy of prematurity or Coats’ disease will be seen at this end stage. Angiogenic factors released by the ischaemic retina are important in the pathogenesis of these retinal vascular diseases. Central retinal artery occlusion, posterior ciliary artery occlusion, ophthalmic artery occlusion, hypertension and disseminated intravascular coagulation are rarely associated with neovascular glaucoma. Choroidal neovascularisation (disciform degeneration) and age related macular degeneration are included in this chapter although they do not per se lead to anterior segment neovascularisation.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Bek T. Capillary closure secondary to retinal vein occlusion. A morphological, histopathological, and immunohistochemical study. Acta Ophthalmol Scand. 1998;76:643–8.

    PubMed  CAS  Google Scholar 

  2. Schultz GS, Grant MB. Neovascular growth factors. Eye. 1991;5:170–80.

    PubMed  Google Scholar 

  3. Pierce EA, Avery RL, Foley ED, Aiello LP, Smith LE. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci U S A. 1995;92(3):905–9.

    PubMed  CAS  Google Scholar 

  4. Petty RG, Pearson JD, Morgan DML, Mahler RFB. Stimulation of endothelial cell growth by sera from diabetic patients with retinopathy. Lancet. 1988;i(8579):208–11.

    Google Scholar 

  5. Aiello LP, Northrup JM, Keyt BA, Tagaki H, Iwamoto MA. Hypoxic regulation of vascular endothelial growth factor in retinal cells. Arch Ophthalmol. 1995;13:1538–44.

    Google Scholar 

  6. Casey R, Li WW. Factors controlling ocular angiogenesis. Am J Ophthalmol. 1997;124:521–9.

    PubMed  CAS  Google Scholar 

  7. Lopez PF, Sippy BD, Lambert HM, Thach AB, Hinton DR. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest Ophthalmol Vis Sci. 1996;37(5):855–68.

    PubMed  CAS  Google Scholar 

  8. Kliffen M, Sharma HS, Mooy CM, Kerkvliet S, de Jong PT. Increased expression of angiogenic growth factors in age-related maculopathy. Br J Ophthalmol. 1997;81(2):154–62.

    PubMed  CAS  Google Scholar 

  9. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331(22):1480–7.

    PubMed  CAS  Google Scholar 

  10. Adamis AP, Miller JW, Bernal MT, D’Amico DJ, Folkman J, Yeo TK, et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol. 1994;118(4):445–50.

    PubMed  CAS  Google Scholar 

  11. Miller JW, Adamis AP, Shima DT, D’Amore PA, Moulton RS, O’Reilly MS, et al. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol. 1994;145(3):574–84.

    PubMed  CAS  Google Scholar 

  12. Boyd SR, Zachary I, Chakravarthy U, Allen GJ, Wisdom GB, Cree IA, et al. Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion. Arch Ophthalmol. 2002;120(12):1644–50.

    PubMed  CAS  Google Scholar 

  13. Noma H, Minamoto A, Funatsu H, Tsukamoto H, Nakano K, Yamashita H, et al. Intravitreal levels of vascular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2006;244(3):309–15.

    PubMed  CAS  Google Scholar 

  14. Murata T, Ishibashi T, Khalil A, Hata Y, Yoshikawa H, Inomata H. Vascular endothelial growth factor plays a role in hyperpermeability of diabetic retinal vessels. Ophthalmic Res. 1995;27(1):48–52.

    PubMed  CAS  Google Scholar 

  15. Mathews MK, Merges C, McLeod DS, Lutty GA. Vascular endothelial growth factor and vascular permeability changes in human diabetic retinopathy. Invest Ophthalmol Vis Sci. 1997;38(13):2729–41.

    PubMed  CAS  Google Scholar 

  16. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9:669–76.

    PubMed  CAS  Google Scholar 

  17. Gragoudas ES, Adamis AP, Cunningham Jr ET, Feinsod M, Guyer DR. VEGF inhibition study in ocular neovascularization clinical trial group: pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351:2805–16.

    PubMed  CAS  Google Scholar 

  18. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY. MARINA Study Group: Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419–31.

    PubMed  CAS  Google Scholar 

  19. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T. ANCHOR Study Group: Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology. 2009;116:57–65.

    PubMed  Google Scholar 

  20. Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, Edwards AR, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010;117:1064–77.

    PubMed  Google Scholar 

  21. Andreoli CM, Miller JW. Anti-vascular endothelial growth factor therapy for ocular neovascular disease. Curr Opin Ophthalmol. 2007;18:502–8.

    PubMed  Google Scholar 

  22. Bashshur ZF, Haddad ZA, Schakal AR, Jaafar RF, Saad A, Noureddin BN. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: the second year of a prospective study. Am J Ophthalmol. 2009;148(1):59–65.e1. Epub 2009 Apr 18.

    PubMed  CAS  Google Scholar 

  23. Wang H, Chhablani J, Freeman WR, Chan CK, Kozak I, Bartsch DU, Cheng L. Characterization of diabetic microaneurysms by simultaneous fluorescein angiography and spectral-domain optical coherence tomography. Am J Ophthal. 2012;153(5):861–7.e1. Epub 2012 Feb 1.

    PubMed  Google Scholar 

  24. Park UC, Park KH, Kim DM, Yu HG. Ahmed glaucoma valve implantation for neovascular glaucoma after vitrectomy for proliferative diabetic retinopathy. J Glaucoma. 2011;20(7):433–8.

    PubMed  Google Scholar 

  25. Nassiri N, Kamali G, Rahnavardi M, Mohammadi B, Nassiri S, Rahmani L, Nassiri N. Ahmed glaucoma valve and single-plate Molteno implants in treatment of refractory glaucoma: a comparative study. Am J Ophthalmol. 2010;149(6):893–902.

    PubMed  Google Scholar 

  26. Ehlers JP, Spirn MJ, Lam A, Sivalingam A, Samuel MA, Tasman W. Combination intravitreal bevacizumab/panretinal photocoagulation versus panretinal photocoagulation alone in the treatment of neovascular glaucoma. Retina. 2008;28(5):696–702.

    PubMed  Google Scholar 

  27. Ciftci S, Sakalar YB, Unlu K, Keklikci U, Caca I, Dogan E. Intravitreal bevacizumab combined with panretinal photocoagulation in the treatment of open angle neovascular glaucoma. Eur J Ophthal. 2009;19(6):1028–33.

    Google Scholar 

  28. Davidorf FH, Mouser JG, Derick RJ. Rapid improvement of rubeosis iridis from a single bevacizumab (Avastin) injection. Retina. 2006;26:354–6.

    PubMed  Google Scholar 

  29. Wakabayashi T, Oshima Y, Sakaguchi H, Ikuno Y, Miki A, Gomi F, et al. Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal disease in 41 consecutive cases. Ophthalmology. 2008;115(9):1571–80.

    PubMed  Google Scholar 

  30. Moraczewski AL, Lee RK, Palmberg PF, Rosenfeld PJ, Feuer WJ. Outcomes of treatment of neovascular glaucoma with intravitreal bevacizumab. Br J Ophthalmol. 2009;93:589–93.

    PubMed  CAS  Google Scholar 

  31. Yazdani S, Hendi K, Pakravan M, Mahdavi M, Yaseri M. Intravitreal bevacizumab for neovascular glaucoma: a randomized controlled trial. J Glaucoma. 2009;18(8):632–7.

    PubMed  Google Scholar 

  32. Saito Y, Higashide T, Takeda H, Ohkubo S, Sugiyama K. Beneficial effects of preoperative intravitreal bevacizumab on trabeculectomy outcomes in neovascular glaucoma. Acta Ophthalmol. 2010;88(1):96–102.

    PubMed  CAS  Google Scholar 

  33. Takihara Y, Inatani M, Kawaji T, Fukushima M, Iwao K, Iwao M, et al. Combined intravitreal bevacizumab and trabeculectomy with mitomycin C versus trabeculectomy with mitomycin C alone for neovascular glaucoma. J Glaucoma. 2011;20(3):196–201.

    PubMed  Google Scholar 

  34. Manschot WA, Lee WR. Retinal neovascularisation arising from hyalinised blood vessels. Graefes Arch Clin Exp Ophthalmol. 1984;222:63–70.

    PubMed  CAS  Google Scholar 

  35. Hiscott P, Cooling RJ, Rosen P, Garner A. The pathology of abortive neovascular outgrowths from the retina. Graefes Arch Clin Exp Ophthalmol. 1992;230:531–6.

    PubMed  CAS  Google Scholar 

  36. Marshall GE, Konstas AG, Lee WR. Ultrastructural distribution of collagens types I–VI in ageing human retinal vessels. Br J Ophthalmol. 1990;74:228–32.

    PubMed  CAS  Google Scholar 

  37. Cugati S, Wang JJ, Rochtchina E, Mitchell P. Ten-year incidence of retinal vein occlusion in an older population: the Blue Mountains Eye Study. Arch Ophthalmol. 2006;124:726–32.

    PubMed  Google Scholar 

  38. Bunce C, Xing W, Wormald R. Causes of blind and partial sight certifications in England and Wales: April 2007–March 2008. Eye (Lond). 2010;24(11):1692–9.

    CAS  Google Scholar 

  39. Green WR, Chan CC, Hutchins GM, Terry JM. Central retinal vein occlusion, a prospective study of 29 eyes of 28 cases. Retina. 1981;1:27–55.

    PubMed  CAS  Google Scholar 

  40. Taylor AW, Sehu KW, Lee WR, Williamson TW. Morphometric assessment of the central retinal artery and vein in the optic nerve head. Can J Ophthalmol. 1993;28:320–4.

    PubMed  CAS  Google Scholar 

  41. Williamson TH. Central retinal vein occlusion: what’s the story? Br J Ophthalmol. 1997;81:691–7.

    Google Scholar 

  42. Bowers DK, Finklelstein D, Wolff SM, Green WR. Branch retinal vein occlusion. A clinicopathologic case report. Retina. 1987;7:252–9.

    PubMed  CAS  Google Scholar 

  43. Bunce C, Wormald R. Causes of blind certifications in England and Wales: April 1999–March 2000. Eye (Lond). 2008;22(7):905–11.

    CAS  Google Scholar 

  44. The Royal College of Ophthalmologists. Preferred practice guidelines. Diabetic retinopathy screening (DRS) and the ophthalmology clinic set up in England. 2010. http://www.rcophth.ac.uk/page.asp?section.451&sectionTitle.Clinical.Guidelines. Accessed 9 Oct 2012.

  45. Bresnick GH. Background diabetic retinopathy. In: Ryan SJ, editor. Retina. St. Louis: CV Mosby; 1989. p. 327–66.

    Google Scholar 

  46. Archer DB. Diabetic retinopathy: some cellular, molecular and therapeutic considerations. Eye. 1999;13:497–523.

    PubMed  Google Scholar 

  47. Antonetti DA, Lieth E, Barber AJ, Gardner TW. Molecular mechanisms of vascular permeability in diabetic retinopathy. Semin Ophthalmol. 1999;14(4):240–8. Review.

    PubMed  CAS  Google Scholar 

  48. Davis MD. Proliferative diabetic retinopathy. In: Ryan SJ, editor. Retina. St. Louis: CV Mosby; 1989. p. 367–402.

    Google Scholar 

  49. Michael JC, de Veneccia G, Bresnick GH. Macular heterotopia in proliferative diabetic retinopathy. Arch Ophthalmol. 1994;112:1455–9.

    PubMed  CAS  Google Scholar 

  50. Faulborn J, Ardjomand N. Tractional retinoschisis in proliferative diabetic retinopathy: a histopathological study. Graefes Arch Clin Exp Ophthalmol. 2000;238:40–4.

    PubMed  CAS  Google Scholar 

  51. Ishibashi T, Murata T, Kohno T, Ohnishi Y, Inomata H. Peripheral choriovitreal neovascularization in proliferative diabetic retinopathy: histopathologic and ultrastructural study. Ophthalmologica. 1999;213:154–8.

    PubMed  CAS  Google Scholar 

  52. Anderson HR, Stitt AW, Gardiner TA, Archer DB. Diabetic retinopathy: morphometric analysis of basement membrane thickening of capillaries in different retinal layers within arterial and venous environments. Br J Ophthalmol. 1995;79:1120–3.

    PubMed  CAS  Google Scholar 

  53. Attawia MA, Nayak RC. Circulating antipericyte autoantibodies in diabetic retinopathy. Retina. 1999;19:390–400.

    PubMed  CAS  Google Scholar 

  54. Kohner EM. Diabetic retinopathy. Br Med J. 1993;307:1195–9.

    CAS  Google Scholar 

  55. Stefansson E. Ocular oxygenation and the treatment of diabetic retinopathy. Surv Ophthalmol. 2006;51:364–80.

    PubMed  Google Scholar 

  56. Chistiakov DA. Diabetic retinopathy: Pathogenic mechanisms and current treatments. Diabetes Metab Syndr. 2011;5(3):165–72.

    PubMed  Google Scholar 

  57. Tremolada G, Del Turco C, Lattanzio R, Maestroni S, Maestroni A, Bandello F, Zerbini G. The role of angiogenesis in the development of proliferative diabetic retinopathy: impact of intravitreal anti-VEGF treatment. Exp Diabetes Res. 2012;728325. Epub 2012 Apr 11. Review

    Google Scholar 

  58. Ferris FLIII, Davis MD, Aiello LM. Treatment of diabetic retinopathy. N Engl J Med. 1999;341:667–78.

    PubMed  Google Scholar 

  59. Wallow IHL, Davis MD. Clinicopathological correlation of xenon arc and argon laser photocoagulation. Arch Ophthalmol. 1979;97:2308–15.

    PubMed  CAS  Google Scholar 

  60. Wallow IH, Sponsel WE, Stevens TS. Clinicopathologic correlation of diode laser burns in monkeys. Arch Ophthalmol. 1991;109:648–53.

    PubMed  CAS  Google Scholar 

  61. Mirshahi A, Roohipoor R, Lashay A, Mohammadi SF, Abdoallahi A, Faghihi H. Bevacizumab-augmented retinal laser photocoagulation in proliferative diabetic retinopathy: a randomized double-masked clinical trial. Eur J Ophthalmol. 2008;2:263–9.

    Google Scholar 

  62. Tonello M, Costa RA, Almeida FP, Barbosa JC, Scott IU, Jorge R. Panretinal photocoagulation versus PRP plus intravitreal bevacizumab for high-risk proliferative diabetic retinopathy (IBeHi study). Acta Ophthalmol. 2008;86:385–9.

    PubMed  CAS  Google Scholar 

  63. Moradian S, Ahmadieh H, Malihi M, Soheilian M, Dehghan MH, Azarmina M. Intravitreal bevacizumab in active progressive proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2008;246(12):1699–705.

    PubMed  CAS  Google Scholar 

  64. Yeh PT, Yang CM, Lin YC, Chen MS, Yang CH. Bevacizumab pretreatment in vitrectomy with silicone oil for severe diabetic retinopathy. Retina. 2009;29(6):768–74.

    PubMed  Google Scholar 

  65. Ahmadieh H, Shoeibi N, Entezari M, Monshizadeh R. Intravitreal bevacizumab for prevention of early postvitrectomy hemorrhage in diabetic patients: a randomized clinical trial. Ophthalmology. 2009;116:1943–8.

    PubMed  Google Scholar 

  66. Erdol H, Turk A, Akyol N, Imamoglu HI. The results of intravitreal bevacizumab injections for persistent neovascularizations in proliferative diabetic retinopathy after photocoagulation therapy. Retina. 2010;30:570–7.

    PubMed  Google Scholar 

  67. De Juan E, Machemer R. Ultrastructural characteristics of new vessels in proliferative diabetic retinopathy. Am J Ophthalmol. 1988;105:491–9.

    PubMed  Google Scholar 

  68. Nork TM, Wallow IHL, Sramek SJ, Anderson G. Müller’s cell involvement in proliferative diabetic retinopathy. Arch Ophthalmol. 1987;105:1424–9.

    PubMed  CAS  Google Scholar 

  69. Jones JH, Kroll AJ, Lou PL, Ryan EA. Coats’ disease. Int Ophthalmol Clin. 2001;41:189–98.

    PubMed  CAS  Google Scholar 

  70. Shields JA, Shields CL, Honavar SG, Demirci H, Cater J. Classification and management of Coats disease: the 2000 Proctor lecture. Am J Ophthalmol. 2001;131:572–83.

    PubMed  CAS  Google Scholar 

  71. Shienbaum G, Tasman WS. Coats disease: a lifetime disease. Retina. 2006;26:422–4.

    PubMed  Google Scholar 

  72. Andonegui J, Aranguren M, Berástegui L. Coats disease of adult onset. Arch Soc Esp Oftalmol. 2008;83(117):120.

    Google Scholar 

  73. Wang KY, Cheng CK. A combination of intravitreal bevacizumab injection with tunable argon yellow laser photocoagulation as a treatment for adult-onset Coats’ disease. J Ocul Pharmacol Ther. 2011;27:525–30.

    PubMed  Google Scholar 

  74. Shields JA, Shields CL, Honavar SG, Demirci H. Clinical variations and complications of Coats disease in 150 cases: the 2000 Sanford Gifford Memorial Lecture. Am J Ophthalmol. 2001;131:561–71.

    PubMed  CAS  Google Scholar 

  75. Couvillion SS, Margolis R, Mavrofjides E, Hess D, Murray TG. Laser treatment of Coats’ disease. J Pediatr Ophthalmol Strabismus. 2005;42:367–8.

    PubMed  Google Scholar 

  76. Mulvihill A, Morris B. A population-based study of Coats disease in the United Kingdom. II. Investigation, treatment, and outcomes. Eye. 2010;24:1802–7.

    PubMed  CAS  Google Scholar 

  77. Ozdamar Y, Berker N, Batman C, Zilelioglu O. Vitreoretinal surgery in advanced Coats disease. Retin Cases Brief Rep. 2009;3:57–9.

    Google Scholar 

  78. Yamashita T, Kawamura H, Kojo N, Ohji M. A case of Coats’ disease with visual recovery from no light perception vision after vitrectomy. Jpn J Ophthalmol. 2011;55:78–80.

    PubMed  CAS  Google Scholar 

  79. Bergstrom CS, Hubbard 3rd GB. Combination intravitreal triamcinolone injection and cryotherapy for exudative retinal detachments in severe Coats disease. Retina. 2008;28:33–7.

    Google Scholar 

  80. Othman IS, Moussa M, Bouhaimed M. Management of lipid exudates in Coats disease by adjuvant intravitreal triamcinolone: effects and complications. Br J Ophthalmol. 2010;94:606–10.

    PubMed  Google Scholar 

  81. Lin CJ, Hwang JF, Chen YT, Chen SN. The effect of intravitreal bevacizumab in the treatment of Coats disease in children. Retina. 2010;30:617–22.

    PubMed  Google Scholar 

  82. Wells JR, Hubbard 3rd GB. The effect of intravitreal bevacizumab in the treatment of Coats disease in children. Retina. 2011;31:427–8.

    PubMed  Google Scholar 

  83. Goel N, Kumar V, Seth A, Raina UK, Ghosh B. Role of intravitreal bevacizumab in adult onset Coats’ disease. Int Ophthalmol. 2011;31:183–90.

    PubMed  Google Scholar 

  84. Zhao T, Wang K, Ma Y, Jiang YR. Resolution of total retinal detachment in Coats’ disease with intravitreal injection of bevacizumab. Graefes Arch Clin Exp Ophthalmol. 2011;249:1745–6.

    PubMed  Google Scholar 

  85. Steidl SM, Hirose T, Sang D, Hartnett ME. Difficulties in excluding the diagnosis of retinoblastoma in cases of advanced Coats’ disease: a clinicopathologic report. Ophthalmologica. 1996;210:336–40.

    PubMed  CAS  Google Scholar 

  86. Fernandes BF, Odashiro AN, Maloney S, Zajdenweber ME, Lopes AG, Burnier Jr MN. Clinical -histopathological correlation in a case of Coats’ disease. Diagn Pathol. 2006;1:24.

    PubMed  Google Scholar 

  87. Mottow-Lippa L, Tso MOM, Peyman GA, Chejfec G. Von Hippel angiomatosis. A light, electron microscopic and immunoperoxidase characterisation. Ophthalmology. 1983;90:848–55.

    PubMed  CAS  Google Scholar 

  88. Grossniklaus HE, Thomas JW, Vigneswaran N, Jarrett II WH. Retinal hemangioblastoma. A histologic, immunohistochemical, and ultrastructural evaluation. Ophthalmology. 1992;99:140–5.

    PubMed  CAS  Google Scholar 

  89. Nowilaty SR, Al-Shamsi HN, Al-Khars W. Idiopathic juxtafoveolar retinal telangiectasis: a current review. Middle East Afr J Ophthalmol. 2010;17(3):224–41.

    PubMed  Google Scholar 

  90. Gass JD, Blodi BA. Idiopathic juxtafoveolar retinal telangiectasis. Update of classification and follow-up study. Ophthalmology. 1993;100:1536–46.

    PubMed  CAS  Google Scholar 

  91. Gamulescu MA, Walter A, Sachs H, Helbig H. Bevacizumab in the treatment of idiopathic macular telangiectasia. Graefes Arch Clin Exp Ophthalmol. 2008;246:1189–93.

    PubMed  CAS  Google Scholar 

  92. Yannuzzi LA, Bardal AM, Freund KB, Chen KJ, Eandi CM, Blodi B. Idiopathic macular telangiectasia. Arch Ophthalmol. 2006;124:450–60.

    PubMed  Google Scholar 

  93. Eliassi-Rad B, Green WR. Histopathologic study of presumed parafoveal telangiectasis. Retina. 1999;19:332–5.

    PubMed  CAS  Google Scholar 

  94. Mandal S, Venkatesh P, Abbas Z, Vohra R, Garg S. Intravitreal bevacizumab (Avastin) for subretinal neovascularization secondary to type 2A idiopathic juxtafoveal telangiectasia. Graefes Arch Clin Exp Ophthalmol. 2007;245:1825–9.

    PubMed  CAS  Google Scholar 

  95. Ruys J, De Laey JJ, Vanderhaeghen Y, Van Aken EH. Intravitreal bevacizumab (Avastin) for the treatment of bilateral acquired juxtafoveal retinal telangiectasis associated with choroidal neovascular membrane. Eye (Lond). 2007;21:1433–4.

    CAS  Google Scholar 

  96. Mavrakanas N, Mendrinos E, Pournaras CJ, Salzmann J. Intravitreal ranibizumab and bevacizumab for bilateral subretinal neovascularization secondary to idiopathic juxtafoveal telangiectasia type 2A. Acta Ophthalmol. 2009;87:930–2.

    PubMed  Google Scholar 

  97. Smith LE. Pathogenesis of retinopathy of prematurity. Semin Neonatol. 2003;8:469–73.

    PubMed  Google Scholar 

  98. Tasman W, Patz A, McNamara JA, Kaiser RS, Trese MT, Smith BT. Retinopathy of prematurity: the life of a lifetime disease. Am J Ophthalmol. 2006;141:167–74.

    PubMed  Google Scholar 

  99. Jin J, Feng J, Gu MH, Shi CP, Zheng XY, Zhu HH, et al. Analysis on the result of retinopathy of prematurity screening in 1225 premature infants. Zhonghua Er Ke Za Zhi. 2010;48(11):829–33. Chinese.

    PubMed  Google Scholar 

  100. Stone J, Chan-Ling T, Pe’er J, Itin A, Gnessin H, Keshet E. Roles of vascular endothelial growth factor and astrocyte degeneration in the genesis of retinopathy of prematurity. Invest Ophthalmol Vis Sci. 1996;37:290–9.

    PubMed  CAS  Google Scholar 

  101. Gariano RF, Kalina RE, Hendrikson AE. Normal and pathological mechanisms in retinal vascular development. Surv Ophthalmol. 1996;40:481–90.

    PubMed  CAS  Google Scholar 

  102. Hellström A, Carlsson B, Niklasson A, Segnestam K, Boguszewski M, de Lacerda L, et al. IGF-I is critical for normal vascularisation of the human retina. J Clin Endocrinol Metab. 2002;87:3413–6.

    PubMed  Google Scholar 

  103. Chen J, Smith LEH. Retinopathy of prematurity. Angiogenesis. 2007;10(2):133–40.

    PubMed  Google Scholar 

  104. CCRP—Committee for the Classification of Retinopathy of Prematurity. An international classification of retinopathy of prematurity. Arch Ophthalmol. 1984;102:1130–4.

    Google Scholar 

  105. CCRPG. Multicentre trial of cryotherapy for ROP. Arch Ophthalmol. 1988;106:471–9.

    Google Scholar 

  106. International Committee for the Classification of Retinopathy of Prematurity. The international classification of retinopathy of prematurity revisited. Arch Ophthalmol. 2005;123:991–9.

    Google Scholar 

  107. Altinsoy HI, Mutlu FM, Gungor R, Sarici SU. Combination of laser photocoagulation and intravitreal bevacizumab in aggressive posterior retinopathy of prematurity. Ophthalmic Surg Lasers Imaging. 2010;9:1–5.

    Google Scholar 

  108. Law JC, Recchia FM, Morrison DG, Donahue SP, Estes RL. Intravitreal bevacizumab as adjunctive treatment for retinopathy of prematurity. J AAPOS. 2010;14:6–10.

    PubMed  Google Scholar 

  109. Lee JY, Chae JB, Yang SJ, Yoon YH, Kim JG. Effects of intravitreal bevacizumab and laser in retinopathy of prematurity therapy on the development of peripheral retinal vessels. Graefes Arch Clin Exp Ophthalmol. 2010;248:1257–62.

    PubMed  CAS  Google Scholar 

  110. Foos RY. Retinopathy of prematurity. Pathologic correlation of clinical stages. Retina. 1987;7:260–76.

    PubMed  CAS  Google Scholar 

  111. McLeod DS, Merges C, Fukushima A, Goldberg MF, Lutty GA. Histopathologic features of neovascularization in sickle cell retinopathy. Am J Ophthalmol. 1997;124:455–72.

    PubMed  CAS  Google Scholar 

  112. Nagpal KC, Patrianakos D, Asdourian GK, Goldberg MF, Rabb M, Jampol L. Spontaneous regression (autoinfarction) of proliferative sickle retinopathy. Am J Ophthalmol. 1975;80:885–92.

    PubMed  CAS  Google Scholar 

  113. Condon PI, Serjeant GR. Behaviour of untreated proliferative sickle retinopathy. Br J Ophthalmol. 1980;64:404–11.

    PubMed  CAS  Google Scholar 

  114. Fox PD, Vessey SJ, Forshaw ML, Serjeant GR. Influence of genotype on the natural history of untreated proliferative sickle retinopathy—an angiographic study. Br J Ophthalmol. 1991;75:229–31.

    PubMed  CAS  Google Scholar 

  115. Siqueira RC, Costa RA, Scott IU, Cintra LP, Jorge R. Intravitreal bevacizumab (Avastin) injection associated with regression of retinal neovascularization caused by sickle cell retinopathy. Acta Ophthalmol Scand. 2006;84:834–5.

    PubMed  Google Scholar 

  116. Shaikh S. Intravitreal bevacizumab (Avastin) for the treatment of proliferative sickle retinopathy. Indian J Ophthalmol. 2008;256:259.

    Google Scholar 

  117. Gupta A, Dhawahir-Scala F, Smith A, Young L, Charles S. Radiation retinopathy: case report and review. BMC Ophthalmol. 2007;7:6.

    PubMed  Google Scholar 

  118. Gupta A, Muecke JS. Treatment of radiation maculopathy with intravitreal injection of bevacizumab (Avastin). Retina. 2008;28:964–8.

    PubMed  Google Scholar 

  119. Finger PT, Mukkamala SK. Intravitreal anti-VEGF bevacizumab (Avastin) for external beam related radiation retinopathy. Eur J Ophthalmol. 2011;21(4):446–51.

    PubMed  Google Scholar 

  120. Warburg M. Norrie disease: a congenital oculo-acoustico-cerebral degeneration. Acta Ophthalmol. 1966;89(Suppl):1–147.

    Google Scholar 

  121. Berger W. Molecular dissection of Norrie disease. Acta Anat (Basel). 1998;162:95–100.

    CAS  Google Scholar 

  122. Berger W, van de PD, Warburg M, Gal A, Bleeker-Wagemakers L, de Silva H, et al. Mutations in the candidate gene for Norrie disease. Hum Mol Genet. 1992;1:461–5.

    PubMed  CAS  Google Scholar 

  123. Meindl A, Berger W, Meitinger T, van de Pol D, Achatz H, Dörner C, et al. Norrie disease is caused by mutations in an extracellular protein resembling C-terminal globular domain of mucins. Nat Genet. 1992;2:139–43.

    PubMed  CAS  Google Scholar 

  124. Ye X, Wang Y, Cahill H, Yu M, Badea TC, Smallwood PM, et al. Norrin, frizzled-4, and Lrp5 signaling in endothelial cells controls a genetic program for retinal vascularization. Cell. 2009;139:285–98.

    PubMed  CAS  Google Scholar 

  125. Ohlmann A, Seitz R, Braunger B, Seitz D, Bösl MR, Tamm ER. Norrin promotes vascular regrowth after oxygen induced retinal vessel loss and suppresses retinopathy in mice. J Neurosci. 2010;30:183–93.

    PubMed  CAS  Google Scholar 

  126. Ohlmann A, Scholz M, Goldwich A, Chauhan BK, Hudl K, Ohlmann AV, et al. Ectopic norrin induces growth of ocular capillaries and restores normal retinal angiogenesis in Norrie disease mutant mice. J Neurosci. 2005;25:1701–10.

    PubMed  CAS  Google Scholar 

  127. Seitz R, Hackl S, Seibuchner T, Tamm ER, Ohlmann A. Norrin mediates neuroprotective effects on retinal ganglion cells via activation of the Wnt/beta-Catenin signaling pathway and the induction of neuroprotective growth factors in Müller cells. J Neurosci. 2010;30:5998–6010.

    PubMed  CAS  Google Scholar 

  128. Blodi FC, Hunter WS. Norrie’s disease in North America. Doc Ophthalmol. 1969;26:434–50.

    PubMed  CAS  Google Scholar 

  129. Nadol JB, Eavey RD, Liberfarb RM, Merlchant SN, Williams R, Climenhager D, Albert DM. Histopathology of the ears, eyes and brain in Norrie’s disease (oculoacousticocerebral degeneration). Am J Otolaryngol. 1990;11:112–24.

    PubMed  Google Scholar 

  130. Enyedi LB, de Juan E, Gaitan A. Ultrastructural study of Norrie’s disease. Am J Ophthalmol. 1991;111:439–45.

    PubMed  CAS  Google Scholar 

  131. Chow CC, Kiernan DF, Chau FY, Blair MP, Ticho BH, Galasso JM, Shapiro MJ. Laser photocoagulation at birth prevents blindness in Norrie’s disease diagnosed using amniocentesis. Ophthalmology. 2010;117(12):2402–6.

    PubMed  Google Scholar 

  132. Kiernan DF, Blair MP, Shapiro MJ. In utero diagnosis of Norrie disease and early laser preserves visual acuity. Arch Ophthalmol. 2010;128(10):1382.

    PubMed  Google Scholar 

  133. Ko MK, Kim DS. Posterior segment neovascularization associated with acute ophthalmic artery obstruction. Retina. 2000;20:384–8.

    PubMed  CAS  Google Scholar 

  134. Triplett DA, Asherson RA. Pathophysiology of the catastrophic antiphospholipid syndrome. Am J Haematol. 2000;65:154–9.

    CAS  Google Scholar 

  135. Delaney WV, Torrisi PF, Hampton GR. Haemorrhagic peripheral pigment epithelial disease. Arch Ophthalmol. 1988;106:646–50.

    PubMed  Google Scholar 

  136. Edwards AO, Ritter RIII, Abel KJ, Manning A, Panhuysen C, Farrer LA. Complement factor H polymorphism and age-related macular degeneration. Science. 2005;308:421–4.

    PubMed  CAS  Google Scholar 

  137. Issa PC, Change NV, Scholl HPN. The significance of the complement system for the pathogenesis of age-related macular degeneration—current evidence and translation into clinical application. Graefes Arch Clin Exp Ophthalmol. 2011;249:163–74.

    CAS  Google Scholar 

  138. Nowak JZ. Age-related macular degeneration (AMD): pathogenesis and therapy. Pharmacol Rep. 2006;58:353–63.

    PubMed  CAS  Google Scholar 

  139. Grisanti S, Tatar O. The role of vascular endothelial growth factor and other endogenous interplayers in age-related macular degeneration. Prog Retin Eye Res. 2008;27:372–90.

    PubMed  CAS  Google Scholar 

  140. Nozaki M, Raisler BJ, Sakurai E, Sarma JV, Barnum SR, Lambris JD, Chen Y, Zhang K, Ambati BK, Baffi JZ, Ambati J. Drusen complement components C3a and C5a promote choroidal neovascularization. Proc Natl Acad Sci U S A. 2006;103:2328–33.

    PubMed  CAS  Google Scholar 

  141. Rohrer B, Long Q, Coughlin B, Wilson RB, Huang Y, Qiao F, Tang PH, Kunchithapautham K, Gilkeson GS, Tomlinson S. A targeted inhibitor of the alternative complement pathway reduces angiogenesis in a mouse model of age-related macular degeneration. Invest Ophthalmol Vis Sci. 2009;50:3056–64.

    PubMed  Google Scholar 

  142. Pons M, Marin-Castano ME. Cigarette smoke-related hydroquinone dysregulates MCP-1, VEGF and PEDF expression in retinal pigment epithelium in vitro and in vivo. PLoS One. 2011;6(2):e16722.

    PubMed  CAS  Google Scholar 

  143. Beatty S, Koh H-H, Henson D, Boulton M. The role of oxidative stress in the pathogenesis of age related macular degeneration. Surv Ophthalmol. 2000;45:115–34.

    PubMed  CAS  Google Scholar 

  144. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol. 2001;119:1417–36.

    Google Scholar 

  145. Green WR, Macdonnel PY, Yeo JH. Pathologic features of senile macular degeneration. Ophthalmology. 1985;92:615–27.

    PubMed  CAS  Google Scholar 

  146. Bressler SH, Silva JC, Bressler NM. Clinicopathological correlation of occult choroidal neovascularisation in age-related macular degeneration. Arch Ophthalmol. 1992;110:827–32.

    PubMed  CAS  Google Scholar 

  147. Feeney Burns L, Burns RP, Gao C-L. Age related macular changes in humans over 90 years old. Am J Ophthalmol. 1990;109:265–78.

    PubMed  CAS  Google Scholar 

  148. Klein R, Meuer SM, Knudtson MD, Iyengar SK, Klein BE. The epidemiology of retinal reticular drusen. Am J Ophthalmol. 2008;145:317–26.

    PubMed  Google Scholar 

  149. Zweifel SA, Imamura Y, Spaide TC, Fujiwara T, Spaide RF. Prevalence and significance of subretinal drusenoid deposits (reticular pseudodrusen) in age-related macular degeneration. Ophthalmology. 2010;117:1775–81.

    PubMed  Google Scholar 

  150. Abdelsalam A, Del Priore L, Zarbin MA. Drusen in age related macular degeneration: pathogenesis, natural course and laser photocoagulation-induced regression. Surv Ophthalmol. 1999;44:1–29.

    PubMed  CAS  Google Scholar 

  151. Spraul CW, Lang GE, Grossniklaus HE, Lang GK. Histologic and morphometric analysis of the choroid, Bruch’s membrane, and retinal pigment epithelium in post-mortem eyes with age related macular degeneration and histologic examination of surgically excised choroidal neovascular membranes. Surv Ophthalmol. 1999;44 Suppl 1:S10–32.

    PubMed  Google Scholar 

  152. Sarks JP, Sarks SH, Killingsworth MC. Evolution of soft drusen in age-related macular degeneration. Eye. 1994;8:269–83.

    PubMed  Google Scholar 

  153. Green WR, Enger C. Age-related macular degeneration histopathologic study. Ophthalmology. 1993;100:1519–35.

    PubMed  CAS  Google Scholar 

  154. Loeffler KU, Lee WR. Basal linear deposit in the human macula. Graefes Arch Clin Exp Ophthalmol. 1986;224:493–501.

    Google Scholar 

  155. Killingsworth MC. Age related components of Bruch’s membrane in the human eye. Graefes Arch Clin Exp Ophthalmol. 1987;225:406–12.

    PubMed  CAS  Google Scholar 

  156. Killingsworth MC, Sarks P, Sarks SH. Macrophages related to Bruch’s membrane in age related macular degeneration. Eye. 1990;4:613–21.

    PubMed  Google Scholar 

  157. Sarks JP, Sarks SH, Killingsworth MC. Morphology of early choroidal neovascularisation in age-related macular degeneration: correlation with activity. Eye. 1997;11:515–22.

    PubMed  Google Scholar 

  158. Loeffler KU, Lee WR. Terminology of sub-RPE deposits: do we all speak the same language? Br J Ophthalmol. 1998;82:1104–5.

    PubMed  CAS  Google Scholar 

  159. Holz FG, Sheraidah G, Pauleikhoff D, Bird AC. Analysis of lipid deposits extracted from human macular and peripheral Bruch’s membrane. Arch Ophthalmol. 1994;112:402–6.

    PubMed  CAS  Google Scholar 

  160. Bressler NM. Treatment of age-related macular degeneration with photodynamic therapy: photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two year results of 2 randomized clinical trials-tap report 2. Arch Ophthalmol. 2001;119:198–207.

    PubMed  CAS  Google Scholar 

  161. CATT Research Group, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364:1897–908.

    PubMed  CAS  Google Scholar 

  162. Grossniklaus HE, Gass JDM. Clinicopathologic correlations of surgically excised Type 1 and Type 2 submacular choroidal neovascular membranes. Am J Ophthalmol. 1998;126:56–9.

    Google Scholar 

  163. Lafaut BA, Bartz-Schmidt KU, Vanden Broecke C, Aisenbrey S, De Laey JJ, Heimann K. Clinicopathologic correlation in exudative age related macular degeneration: histological differentiation between classic and occult choroidal neovascularisation. Br J Ophthalmol. 2000;84(3):239–43.

    PubMed  CAS  Google Scholar 

  164. Thomas MA, Grand MG, Williams DF, Lee CM, Pesin SR, Lowe MA. Surgical management of subfoveal choroidal neovascularisation. Ophthalmology. 1992;99:952–68.

    PubMed  CAS  Google Scholar 

  165. Gass JDM. Biomicroscopic and histopathologic considerations regarding the feasibility of surgical excision of subfoveal neovascular membranes. Am J Ophthalmol. 1994;118:L285–98.

    Google Scholar 

  166. Nasir MA, Sugino I, Zarbin MA. Decreased choriocapillaris perfusion following surgical excision of choroidal neovascular membranes in age-related macular degeneration. Br J Ophthalmol. 1997;81:481–9.

    PubMed  CAS  Google Scholar 

  167. Castellarin AO, Nasir MA, Sugino IK, Zarbin MA. Clinicopathological correlation of primary and recurrent choroidal neovascularisation following surgical excision in age related macular degeneration. Br J Ophthalmol. 1998;82:480–7.

    PubMed  CAS  Google Scholar 

  168. Thomas MA, Kaplan HJ. Surgical removal of subfoveal neovascularisation in the presumed ocular histoplasmosis syndrome. Am J Ophthalmol. 1991;111:1–7.

    PubMed  CAS  Google Scholar 

  169. Reddy VM, Zamora RL, Kaplan HJ. Distribution of growth factors in subfoveal neovascular membranes in age-related macular degeneration and presumed ocular histoplasmosis syndrome. Am J Ophthalmol. 1995;120(3):291–301.

    PubMed  CAS  Google Scholar 

  170. Sehu KW, Lee WR, editors. Ophthalmic pathology: an illustrated guide for clinicians. Malden: Blackwell Publishing Ltd; 2008. ISBN 9780727917799.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Southern General Hospital, Glasgow, UK

    Fiona Roberts

  2. Western General Hospital, Edinburgh, UK

    Chee Koon Thum

Authors
  1. Fiona Roberts
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chee Koon Thum
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag London

About this chapter

Cite this chapter

Roberts, F., Thum, C.K. (2014). Retinal Vascular Disease. In: Lee's Ophthalmic Histopathology. Springer, London. https://doi.org/10.1007/978-1-4471-2476-4_4

Download citation

  • DOI: https://doi.org/10.1007/978-1-4471-2476-4_4

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-4471-2475-7

  • Online ISBN: 978-1-4471-2476-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation